Amount Raised
$19 Million
Round Type
Funding Round
ClevelandBiotechnologyFinancial ServicesHealth CareMedicalHealth DiagnosticsDescription
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that it has closed a Series D round of $17.4 million. The round was led by LYFE Capital, with participation from existing investors including Cleveland Clinic and others. Following the close of the round, the company received a term sheet for a $2M convertible note, expected to close shortly. Funds raised will be used to expand commercialization of IsoPSA—the company’s first diagnostic test, designed to enhance early detection of prostate cancer—as well as to expand internal infrastructure and operations to support platform development for other tests, including breast and lung cancer.
Who to call at Cleveland Diagnostics, and when
A new round usually means Cleveland Diagnostics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Cleveland Diagnostics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Cleveland Diagnostics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Cleveland Diagnostics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Cleveland Diagnostics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Cleveland Diagnostics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.